Type I interferon appears to play a role in disease susceptibility and pathogenesis in several classic connective tissue diseases, at least in some patients. Below, I present evidence supporting this connection, explore potential missing links in pathogenesis and discuss biological treatments that target the pathway. The Type I Interferon Pathway Interferons are a class of…
A 53-year-old man was hospitalized for pericarditis, abdominal lymphadenopathy of unknown origin and non-bloody diarrhea. He was admitted for four days, and then he was discharged home without incident. Two months after his initial presentation, he was readmitted for the evaluation of several new issues, including symmetric arthralgias, hypovolemia with associated electrolyte abnormalities and concurrent…
In a study of bDMARD-naive patients with active PsA and skin disease, ixekizumab proved more efficacious than adalimumab…
SAN FRANCISCO—The 13th International Congress on Systemic Lupus Erythematosus (SLE), held April 5–8, highlighted continuing advances in the fight against lupus, a chronic, inflammatory, autoimmune disease affecting multiple organ systems. The rheumatologist’s ability to control this incurable and life-threatening condition is limited both by its heterogeneous presentation and by the lack of successful treatment options,…
New research by Jose Scher, MD, discussed during the 2019 ACR State-of-the-Art Clinical Symposium, demonstrated how clinicians may be able to modify aspects of the microbiome to predict and boost a patient’s treatment response…
The FDA has approved rizankixumab to treat adults with plaque psoriasis and added boxed warnings to sleep medications…
A recent study evaluated the factors associated with the presence of peripheral manifestations of spondyloarthritis (SpA), which affects more than half of patients with SpA. Researchers found that being older, HLAB27 negative and having a history of psoriasis were associated with these symptoms…
TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s…
SNOWMASS VILLAGE, COLO.—Even in the era of treat to target, cardiovascular disease risk remains elevated and is a major source of mortality and morbidity in patients with rheumatoid arthritis (RA). Screening and management of cardiovascular risk in these patients is critical to ensure these patients are identified and treated. At the 2019 ACR Winter Rheumatology…
Psoriatic arthritis came to be viewed as a distinct disease entity with specific clinical features, genetics and pathophysiology only gradually. One important historic development in this transition was a 1973 paper written by a pair of researchers out of Leeds, England: John M. Moll, BSc, DM, and Verna Wright, MD, FRCP.1 Here we discuss the…